biostudies-literaturePrice AMCenters for Disease Control and PreventionCDC HHS1899-1909https://www.ebi.ac.uk/biostudies/studies/S-EPMC9006785biostudies-literatureUnknown386(20)<h4>Background</h4>Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion and the duration of protection from vaccines in children and adolescents.<h4>Methods</h4>Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading to hospitalization and against critical Covid-19 (i.e., leading to receipt of life support or to death). From July 1, 2021, to February 17, 2022, we enrolled case patients with Covid-19 and controls without Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two The New England journal of medicineBNT162b2 Protection against the Omicron Variant in Children and Adolescents.PMC900678575D30121C10297Nofziger RAPatterson KKelley CPMoran PZambrano LDMalloch LBline KEGlas Gaspers MJohnston MSMartin LMaamari MGertz SJKhan HAOates JNRohlfs CCSchwartz SPOrzel AOHe JTwinem NAMaddux ABHeidemann SMDouglas RLChiotos KSmallcomb LPrice AMBradford TTCarson ISanders CMurdock MBline KBehl SRandolph AGWeller ECullimore MLMack EHRowan CMPeralta HTenforde MWPort EHume JRHakimi DLevy ERPatel MMWolfe ACampbell APMcCadden TPKong MHill SMOvercoming Covid-19 InvestigatorsMurcia-Montoya JDrapeau NMBickford MMSahni LCWalker TCFlori HRKucukak SWakefield LEBoutselis BJTomcany MLBoom JACrane KPhengchomphet KHalasa NBBaida NYates MSkura ALIrby KSanders RCMrotek KGTyppo KVVillarreal-Chico DBhumbra SSBowens CHobbs CVLionetti GStewart LSCvijanovich NZChen SRMack HHarrison VAGolchha MRinehart VHSullivan MStaat MAZinter MSMichelson KNOlson SMNewhams MMKamidani SStumpf MSchuster JEPannaraj PSHussaini LCoates BMLockwood JMBerbert LSmith CChatani BMCameron MARhodes STTarquinio KMHoody LABruno ERSea YJGoertzen LABennett PCfalseBNT162b2 Protection against the Omicron Variant in Children and Adolescents.<h4>Background</h4>Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion and the duration of protection from vaccines in children and adolescents.<h4>Methods</h4>Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading to hospitalization and against critical Covid-19 (i.e., leading to receipt of life support or to death). From July 1, 2021, to February 17, 2022, we enrolled case patients with Covid-19 and controls without Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two 2022-01-01T00:00:00Z2022 May2025-04-25T18:01:45.804Z2025-04-25T18:01:45.804ZS-EPMC90067853535397610.1056/NEJMoa2202826